A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older

• Prif Awduron: Kenji Kawakami (Awdur), Atsushi Nakamura (Awdur), Akira Wakana (Awdur), Temitope A. Folaranmi (Awdur), Tomoharu Iino (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Taylor & Francis Group, 2020-07-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

The 23-valent capsular polysaccharide pneumococcal vaccine (PPSV23) was introduced in Japan's routine immunization schedule October 2014. It was recommended for adults aged 65 years (including those ≥65 during the transition period), and for adults 60-64 with cardiac, renal, or respiratory dysf...